You just read:

FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps

News provided by

Regeneron Pharmaceuticals, Inc.

Mar 08, 2019, 00:59 ET